Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The LAT1 inhibitor JPH203 suppresses the growth of castration-resistant prostate cancer through a CD24-mediated mechanism.
Saito S, Ando K, Sakamoto S, Xu M, Yamada Y, Rii J, Kanaoka S, Wei J, Zhao X, Pae S, Kanesaka M, Goto Y, Sazuka T, Imamura Y, Reien Y, Hamaguchi-Suzuki N, Saito S, Hirayama Y, Hashimoto H, Kanai Y, Ichikawa T, Anzai N. Saito S, et al. Among authors: kanesaka m. Cancer Sci. 2024 Apr 24. doi: 10.1111/cas.16191. Online ahead of print. Cancer Sci. 2024. PMID: 38655663 Free article.
Functional analysis of LAT3 in prostate cancer: Its downstream target and relationship with androgen receptor.
Rii J, Sakamoto S, Sugiura M, Kanesaka M, Fujimoto A, Yamada Y, Maimaiti M, Ando K, Wakai K, Xu M, Imamura Y, Shindo N, Hirota T, Kaneda A, Kanai Y, Ikehara Y, Anzai N, Ichikawa T. Rii J, et al. Among authors: kanesaka m. Cancer Sci. 2021 Sep;112(9):3871-3883. doi: 10.1111/cas.14991. Epub 2021 Jul 8. Cancer Sci. 2021. PMID: 34050700 Free PMC article.
Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer.
Sugiura M, Sato H, Okabe A, Fukuyo M, Mano Y, Shinohara KI, Rahmutulla B, Higuchi K, Maimaiti M, Kanesaka M, Imamura Y, Furihata T, Sakamoto S, Komiya A, Anzai N, Kanai Y, Luo J, Ichikawa T, Kaneda A. Sugiura M, et al. Among authors: kanesaka m. Transl Oncol. 2021 Jan;14(1):100915. doi: 10.1016/j.tranon.2020.100915. Epub 2020 Oct 20. Transl Oncol. 2021. PMID: 33096335 Free PMC article.
The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2.
Maimaiti M, Sakamoto S, Sugiura M, Kanesaka M, Fujimoto A, Matsusaka K, Xu M, Ando K, Saito S, Wakai K, Imamura Y, Nakayama K, Kanai Y, Kaneda A, Ikehara Y, Ikeda JI, Anzai N, Ichikawa T. Maimaiti M, et al. Among authors: kanesaka m. Sci Rep. 2021 Jun 1;11(1):11478. doi: 10.1038/s41598-021-90748-9. Sci Rep. 2021. PMID: 34075107 Free PMC article.
Clinical utility of the prognostic nutritional index in patients with metastatic hormone-sensitive prostate cancer: A retrospective, multicenter, cohort study.
Yamada Y, Sakamoto S, Sato K, Saito S, Kanesaka M, Rii J, Kurokawa K, Tachiwaki D, Fukui Y, Shibata H, Goto Y, Sazuka T, Imamura Y, Nakatsu H, Ichikawa T. Yamada Y, et al. Among authors: kanesaka m. Prostate. 2023 Dec;83(16):1610-1618. doi: 10.1002/pros.24619. Epub 2023 Sep 10. Prostate. 2023. PMID: 37690087
Epigenetic modifications in prostate cancer.
Sugiura M, Sato H, Kanesaka M, Imamura Y, Sakamoto S, Ichikawa T, Kaneda A. Sugiura M, et al. Among authors: kanesaka m. Int J Urol. 2021 Feb;28(2):140-149. doi: 10.1111/iju.14406. Epub 2020 Oct 27. Int J Urol. 2021. PMID: 33111429 Review.
32 results